Europe Cell Line Development Market size crossed USD 1.1 billion in 2020 and is predicted to register a growth of 11% from 2021 to 2027.

Increasing demand of monoclonal antibodies is a key factor driving the market revenue. Monoclonal antibodies work as immunotherapy that supports immune system to respond better and effectively. Monoclonal antibodies play important role in cancer diagnosis and other immune diseases. Rapidly increasing regulatory approval for monoclonal antibody use for various diseases will create new opportunities for market players to expand their product portfolio of cell line development.

Get more details on this report - Request Free Sample PDF

Europe Market, By Product

Reagents & media product segment in the Europe cell line development market is anticipated to expand at nearly 11% CAGR through 2027. Recurring demand for reagents and media during the cell line development process and increasing R&D activities for drug discovery and development are some of the major factors pushing the segment growth.

Europe Market, By Source

Mammalian segment accounted for 72% market share in 2020. Mammalian cells can be made to produce vaccines through viral infection using genetic engineering. Mammalian cell lines are commonly used during the drug development processes. These drugs are use in the treatment of genetic diseases, cancer and more. Advancement in technology will improve the efficiency of highly productive cell lines for large scale production of therapeutic proteins.

Europe Market, By Cell Line Type

Get more details on this report - Request Free Sample PDF

Primary cell line segment held more than 19% market share in 2020. Primary cell line is derived from specific organ of a species, and it isolated directly by using mechanical or enzymatic methods. These cells are further used in research, drug screening and development, manufacturing of biological compounds such as vaccines, therapeutic proteins.

Europe Market, By Country

Germany cell line development market size was over USD 211 million in 2020 and will exhibit more than 10% CAGR during the forecast period. Rising R&D activities for chronic disease and increasing demand of vaccines and therapeutic proteins will spur the industry growth.

Competitive Industry Landscape

Key companies operating in the Europe cell line development market are GVK BIO, Sartorius, WuXi AppTec, Thermo Fisher Scientific, Samsung Biologics, The European Collection of Cell Cultures, Lonza Group, Sigma-Aldrich (Merck), GE Healthcare, and Selexis SA.

Market players are focusing on new product launch, collaborations, mergers and acquisitions to strengthen company position in the industry. For instance, in May 2019, Sartorius Stedim Biotech launched an Ambr 15 cell culture automated microbioreactor system. The system increases lab productivity during cell line development.